(Q38136595)

29 August 2017

title

New drug targets in metastatic melanoma (English)

1 reference

29 August 2017

1 reference

2

Antoni Ribas

1 reference

29 August 2017

Blanca Homet

1

1 reference

29 August 2017

publication date

1 January 2014

1 reference

29 August 2017

1 reference

29 August 2017

volume

232

1 reference

29 August 2017

issue

2

1 reference

29 August 2017

page(s)

134-141

1 reference

Melanoma biology and new targeted therapy

29 August 2017

cites work

1 reference

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

21 January 2018

1 reference

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

KIT gene mutations and copy number in melanoma subtypes

21 January 2018

1 reference

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

A novel transforming gene in a human malignant melanoma cell line

21 January 2018

1 reference

Molecular therapeutic approaches to melanoma

21 January 2018

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies

21 January 2018

1 reference

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

Targeting BRAF for patients with melanoma.

21 January 2018

1 reference

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

21 January 2018

1 reference

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

21 January 2018

1 reference

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

21 January 2018

1 reference

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations

21 January 2018

1 reference

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition

21 January 2018

1 reference

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.

21 January 2018

1 reference

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

21 January 2018

1 reference

Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition

21 January 2018

1 reference

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

21 January 2018

1 reference

MAP kinase signaling and inhibition in melanoma

21 January 2018

1 reference

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.

21 January 2018

1 reference

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

21 January 2018

1 reference

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

21 January 2018

1 reference

Novel Ras antagonist blocks human melanoma growth

21 January 2018

1 reference

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors

21 January 2018

1 reference

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

21 January 2018

1 reference

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

21 January 2018

1 reference

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

21 January 2018

1 reference

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure

21 January 2018

1 reference

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

KIT as a therapeutic target in metastatic melanoma

21 January 2018

1 reference

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

21 January 2018

1 reference

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates

21 January 2018

1 reference

A phase 2 trial of dasatinib in advanced melanoma

21 January 2018

1 reference

Sunitinib therapy for melanoma patients with KIT mutations

21 January 2018

1 reference

Cytokine-based therapy and biochemotherapy for advanced melanoma

21 January 2018

1 reference

Current developments in cancer vaccines and cellular immunotherapy

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

21 January 2018

1 reference

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

PD-1 and PD-1 ligands: from discovery to clinical application

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

New challenges in endpoints for drug development in advanced melanoma

21 January 2018

1 reference

Targeted therapies to improve tumor immunotherapy

21 January 2018

1 reference

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

21 January 2018

1 reference

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

21 January 2018

1 reference

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function

21 January 2018

1 reference

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy

21 January 2018

1 reference

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

21 January 2018

1 reference

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma

21 January 2018

1 reference

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

A central role for mTOR kinase in homeostatic proliferation induced CD8+ T cell memory and tumor immunity

21 January 2018

1 reference

The mTOR kinase determines effector versus memory CD8+ T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin

21 January 2018

1 reference

Combining cancer immunotherapy and targeted therapy

21 January 2018

1 reference

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors

21 January 2018

1 reference

Whole-genome sequencing and cancer therapy: is too much ever enough?

21 January 2018

1 reference

Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436)

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PATH.4259

1 reference

29 August 2017

1 reference